11:49 AM EST - Trimel Pharmaceuticals Corporation : announced the appointment of Matthew Pfeffer to its Board of Directors. Pfeffer currently serves as the Corporate Vice President and Chief Financial Officer of MannKind Corporation, a United States based biopharmaceutical company with a market capitalization of approximately $1.8 billion U.S. focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Trimel Pharmaceuticals Corporation
shares T.TRL are trading down $0.005 at $0.50.
